For an IVD team sourcing antibodies, antigens, or small-molecule reagents, the hard part is rarely the first sample. It is the second, third, and hundredth batch — the ones that have to match the first closely enough that your assay's calibration, cut-offs, and released QC data still hold. A raw-material partner that cannot deliver that consistency turns every re-order into a re-validation project. This is the problem Sekbio is built to solve, and it is what we want to talk about at CPHI & PMEC Shenzhen 2026.
Sekbio will be on-site for all three days of the exhibition, September 16–18, 2026, at the Shenzhen Convention & Exhibition Center (SZCEC). This article explains what the event is, who on our team you can meet, and the two capabilities we are putting front and center this year: recombinant antibody expression under an activity-first payment model, and hapten synthesis with one-stop CDMO for small-molecule targets. It also covers how to book a meeting at the show — or a visit to our Shenzhen facility, which is a short drive from the venue.
1. What Is CPHI & PMEC Shenzhen 2026?
CPHI & PMEC Shenzhen 2026 is a pharmaceutical and biotech industry exhibition that runs September 16–18, 2026 at the Shenzhen Convention & Exhibition Center (SZCEC) in Shenzhen, China. It sits within the wider CPHI & PMEC China programme and is positioned around biotech, R&D, and next-generation pharma manufacturing, drawing exhibitors from across the supply chain: ingredients and finished dosage, contract development and manufacturing services, packaging, processing machinery, and laboratory instruments.
| Field | Details |
|---|---|
| Event | CPHI & PMEC Shenzhen 2026 |
| Dates | September 16–18, 2026 (Wed–Fri) |
| Venue | Shenzhen Convention & Exhibition Center (SZCEC), Shenzhen, China |
| Projected scale | 15,000+ visitors, 800+ exhibiting companies, 60+ countries |
| Sekbio focus | Recombinant antibody & antigen expression, hapten synthesis, one-stop IVD raw-material CDMO |
For diagnostics and biopharma teams, the value of a show like this is concentration: upstream reagent suppliers, chemistry partners, and manufacturing services are all in one hall for three days. That makes it an efficient place to pressure-test a supplier on the questions that actually matter later — batch consistency, documentation, lead times, and what happens when a project runs into trouble.
2. Why Meet Sekbio: Your Trusted Antibody Expert
Shenzhen Sekbio Co., Ltd. is a specialized IVD company, founded in 2020 and headquartered in Guangming District, Shenzhen. We develop and manufacture high-performance immunoreagents — monoclonal antibodies, recombinant antigens, and small-molecule (hapten) conjugates — and supply them to more than 200 IVD brands across 30+ countries. Our quality system is certified to ISO 13485, and our products carry CE marking. Full details are on the About Sekbio and Sekbio quality system pages.
The reason to spend 30 minutes with us at CPHI Shenzhen is not the catalog — it is the delivery model behind it. Three customer problems shape how Sekbio works:
- Fear of a failed expression project. Teams hold back on new assays because a custom antibody that does not express is sunk cost. Our answer: Activity Confirmed. Then You Pay.
- Months lost to screening and pair validation. IVD developers routinely spend three to six months finding and validating an antibody pair. Our answer: pairs that are pre-validated on the platform you actually use.
- Re-validation on every new lot. Batch-to-batch variation forces repeated QC and puts assay calibration at risk. Our answer: industrial-scale manufacturing with tight lot-to-lot CV and full ISO 13485 traceability — one validation, consistent performance, every batch.
"Sekbio antibody technology is built around one promise to the IVD customer: validate the reagent once, and trust every batch that follows."
At the show we can walk through where your program sits against those three problems, and whether the right starting point is a catalog antibody pair, a custom expression project, or a full CDMO engagement.
3. Spotlight 1: Recombinant Antibody Expression — Activity Confirmed, Then You Pay
Recombinant antibody expression is the process of taking a defined antibody sequence, expressing it in a mammalian host cell such as CHO or HEK293, purifying the protein, and confirming that it folds and binds its target. For IVD work, it is the route to consistent, animal-free, sequence-defined antibody supply — the opposite of the drift you get from hybridoma lines over time.
Sekbio's expression platform is the engine under every antibody we ship. Its headline parameters:
| Capability | Platform Detail |
|---|---|
| CHO expression | As fast as 7-day delivery, titers up to 2.4 g/L, 800+ completed projects |
| HEK293 expression | 1,000+ proteins expressed, scalable from 40 mL to 20 L |
| Monoclonal antibody development | 8–12 week end-to-end delivery: sequencing, expression, screening, and stable cell line establishment |
| Payment model | Activity Confirmed. Then You Pay. — no functional activity, no charge for the expression work |
IVD Application Note
If you are converting an existing assay from hybridoma-derived to recombinant antibody for regulatory or consistency reasons, bring the current antibody's performance data to the meeting. Sekbio can scope a sequence-to-stable-line project and set expected timelines against your revalidation window.
The Activity Confirmed. Then You Pay. model exists to remove the reason projects stall before they start. Sekbio carries the antibody from sequence through expression and functional testing; if it shows no functional activity, you are not charged for that expression work. With 800+ successful expression projects behind the platform, the commercial risk we are absorbing is a calculated one — but for the customer, it turns "we can't justify the spend" into "let's run it." Technical specifications for both host systems are on the Sekbio antibody and antigen development platform page, and the trade-offs between hosts are covered in our guide to CHO versus HEK293 for IVD antibody production.
4. Spotlight 2: Hapten Synthesis & One-Stop CDMO
The second capability we are highlighting at CPHI Shenzhen is chemistry, not biology. A hapten is a small molecule — a steroid hormone, a vitamin, a therapeutic drug or its metabolite — that is too small to raise an immune response on its own. Before it can be used to generate antibodies or serve as a coating and competition reagent, it has to be chemically derivatized at a chosen site and conjugated to a carrier protein, usually BSA. The derivatization site, linker chemistry, and conjugation ratio all directly affect the sensitivity and stability of the finished immunoassay.
Low sensitivity and poor stability in hapten-based reagents is one of the most common and most underestimated bottlenecks in small-molecule immunoassay development — and the "obvious" derivatization site is often not the best-performing one. Sekbio addresses this with an AI-assisted chemical synthesis platform that narrows the candidate pool of derivatization sites and linker chemistries before wet-lab synthesis, shortening the loop between structural design and real assay sensitivity data.
| CDMO Stage | What Sekbio Does |
|---|---|
| 1. Target & route design | Hapten structural design, AI-assisted derivatization-site and linker screening |
| 2. Synthesis & conjugation | Wet-lab synthesis, carrier conjugation, coupling-ratio and stability characterization |
| 3. Reagent optimization | Antibody pairing or competition-format tuning, sensitivity and specificity data |
| 4. Manufacturing scale-up | Production-line setup, batch-consistent manufacturing, ISO 13485 documentation |
Representative small-molecule projects include a vitamin B12 tracer conjugate, where route optimization improved reaction sensitivity, and progesterone antibody and derivative work focused on structural design and conjugation process control. Because Sekbio runs both the mammalian expression platform and the chemical synthesis platform in-house, a single CDMO engagement can cover protein-based and hapten-based targets together — from a new biomarker or patent all the way to a manufacturable raw material. The antibody and antigen development platform page is the place to start scoping one.
Pro Tip
When you evaluate a hapten CDMO partner, ask whether synthesis, conjugation, and antibody work happen under one roof. Handing a small molecule from a chemistry vendor to a separate antibody house is where coupling-ratio assumptions and sensitivity targets tend to get lost.
5. Book a Meeting — or Visit the Sekbio Facility in Shenzhen
CPHI & PMEC Shenzhen 2026 is on Sekbio's home ground. Our headquarters and labs are in Guangming District, Shenzhen — the same city as SZCEC — so this show is a rare chance to combine a booth conversation with an in-person look at how the reagents are actually made.
Meet the team at the exhibition
Sekbio scientists and business staff will be on-site for all three days. To reserve a specific time — and to get our current stand location — send a note through the Sekbio contact page ahead of the show. Meetings work best when you include:
- Your target analyte or biomarker, and the sample matrix.
- The assay platform you are developing on: ELISA, CLIA, or lateral flow.
- What you need: catalog antibody pairs, a custom expression project, or a hapten / small-molecule CDMO engagement.
- Your rough timeline and volume, so we can bring realistic lead-time and pricing context.
Visit the Sekbio facility
New and existing customers are welcome to visit the Sekbio site during or right after the exhibition. A visit typically covers the antibody expression and purification labs, the small-molecule chemical synthesis area, and the reagent production and QC workflow — the parts of the operation that determine whether batch 100 matches batch 1. Request a visit through the contact page and the team will arrange a time and transport from the venue.
"Come to the booth for the pitch; come to the lab for the proof. Both are open to you at CPHI Shenzhen 2026."
6. Frequently Asked Questions — Sekbio at CPHI & PMEC Shenzhen 2026
What is CPHI & PMEC Shenzhen 2026?
CPHI & PMEC Shenzhen 2026 is a pharmaceutical and biotech industry exhibition held September 16-18, 2026 at the Shenzhen Convention & Exhibition Center (SZCEC) in Shenzhen, China. It brings together companies from across the pharma supply chain - biotech, R&D, contract services, finished dosage, ingredients, machinery, packaging, and laboratory instruments - with organizers projecting more than 15,000 visitors, over 800 exhibiting companies, and 60+ countries represented.
Where is Sekbio exhibiting at CPHI & PMEC Shenzhen 2026?
Sekbio's team will be on-site at the Shenzhen Convention & Exhibition Center for all three days of CPHI & PMEC Shenzhen 2026, September 16-18. To get Sekbio's current stand location and to reserve a specific meeting time, send a message through the Sekbio contact page and the team will confirm the details and a calendar slot before the show.
How do I book a meeting with Sekbio during CPHI Shenzhen?
Use the Sekbio contact page to request a meeting, and include your target analyte or biomarker, the assay platform you are developing (ELISA, CLIA, or lateral flow), and whether you need catalog antibody pairs, a custom recombinant antibody or antigen expression project, or a hapten and small-molecule CDMO engagement. Sekbio will pre-assign a scientist to your slot so the conversation starts with your project rather than a generic company overview.
Can I visit the Sekbio facility in Shenzhen during the exhibition?
Yes. Sekbio is headquartered in Guangming District, Shenzhen - the same city as the exhibition - so CPHI & PMEC Shenzhen 2026 is a practical window for an in-person facility visit. Visitors can see the antibody expression and purification labs, the small-molecule chemical synthesis area, and the reagent production and quality workflow. Request a visit through the Sekbio contact page and the team will arrange transport and a time either during or immediately after the show.
What does "Activity Confirmed. Then You Pay." mean for antibody expression projects?
It is Sekbio's risk-sharing model for recombinant antibody expression. Sekbio takes an antibody from sequence through expression and functional testing, and if the antibody shows no functional activity, the customer is not charged for the expression work. The model is backed by more than 800 successful expression projects and is designed to remove the upfront financial risk that keeps IVD teams from starting a new development project.
What is a hapten CDMO project and does Sekbio offer it?
A hapten CDMO project covers the design, synthesis, and carrier conjugation of a small-molecule derivative - a steroid hormone, vitamin, or drug metabolite - so it can be used to raise antibodies or as a coating and competition reagent in an immunoassay, and then carries that reagent through to manufacturable raw material. Sekbio offers this as part of its one-stop CDMO service, combining AI-assisted route optimization with wet-lab synthesis and QC. Visit the Sekbio antibody and antigen development platform page to discuss a specific small-molecule target.
7. Summary
If you are attending CPHI & PMEC Shenzhen 2026, here is what to take away about meeting Sekbio:
- The event: CPHI & PMEC Shenzhen 2026 runs September 16-18 at SZCEC; Sekbio is on-site all three days.
- The reason to meet: Sekbio is a Shenzhen-based, ISO 13485-certified IVD reagent maker supplying 200+ brands in 30+ countries, built around batch-to-batch consistency so you validate a reagent once.
- Spotlight 1 — antibody expression: CHO delivery as fast as 7 days, titers up to 2.4 g/L, 800+ projects, under an Activity Confirmed. Then You Pay. model.
- Spotlight 2 — hapten CDMO: AI-assisted small-molecule route design plus in-house synthesis, conjugation, antibody work, and manufacturing under one engagement.
- Two ways to engage: book a booth meeting through the contact page, or arrange a visit to the Sekbio facility in Guangming District during or after the show.
To line up a meeting slot or a facility visit before the show, reach the team through the Sekbio contact page, or review the underlying capability on the antibody and antigen development platform page.